Victory Capital Management Inc revealed that they own a 7% stake in Loxo Oncology Inc. (NASDAQ:LOXO) in a Schedule 13G disclosure that was filed with the SEC on Friday, September 23rd. The investor owns 1,519,194 shares of the stock worth approximately $41,018,238. The filing is available through the SEC website at this link.

Other hedge funds have also recently modified their holdings of the company. Adage Capital Partners GP L.L.C. boosted its position in Loxo Oncology by 40.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 700,000 shares of the biopharmaceutical company’s stock worth $19,138,000 after buying an additional 200,000 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Loxo Oncology by 17.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 148,490 shares of the biopharmaceutical company’s stock worth $4,060,000 after buying an additional 21,737 shares in the last quarter. RS Investment Management Co. LLC boosted its position in Loxo Oncology by 7.0% in the second quarter. RS Investment Management Co. LLC now owns 1,505,004 shares of the biopharmaceutical company’s stock worth $34,886,000 after buying an additional 98,038 shares in the last quarter. State Street Corp boosted its position in Loxo Oncology by 7.4% in the first quarter. State Street Corp now owns 133,074 shares of the biopharmaceutical company’s stock worth $3,638,000 after buying an additional 9,142 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Loxo Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 57,068 shares of the biopharmaceutical company’s stock worth $1,560,000 after buying an additional 2,126 shares in the last quarter. 95.46% of the stock is owned by institutional investors.

Shares of Loxo Oncology Inc. (NASDAQ:LOXO) traded up 0.07% during trading on Friday, reaching $27.02. 47,796 shares of the company’s stock traded hands. The company’s market cap is $585.36 million. Loxo Oncology Inc. has a 52-week low of $16.21 and a 52-week high of $35.00. The company’s 50-day moving average is $26.91 and its 200 day moving average is $25.09.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.14. Equities analysts forecast that Loxo Oncology Inc. will post ($2.83) EPS for the current year.

A number of equities analysts recently issued reports on LOXO shares. Zacks Investment Research cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, September 6th. Cowen and Company restated a “buy” rating on shares of Loxo Oncology in a research report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $29.60.

In other news, Director David P. Bonita sold 447,857 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $26.96, for a total value of $12,074,224.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith T. Flaherty sold 14,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $30.00, for a total transaction of $435,000.00. Following the completion of the transaction, the director now owns 45,982 shares of the company’s stock, valued at $1,379,460. The disclosure for this sale can be found here. 44.40% of the stock is currently owned by insiders.

About Loxo Oncology

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

5 Day Chart for NASDAQ:LOXO

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc. (NASDAQ:LOXO).

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.